The latest update is out from Lifecare AS ( (DE:LFC0) ).
Lifecare ASA recently hosted a high-profile symposium in Bergen, Norway, bringing together global experts to discuss advancements in Continuous Glucose Monitoring (CGM) technologies, including their proprietary osmotic-pressure-based sensor. The company also contributed to a global consensus on using GLP-1 receptor agonists in Type 1 Diabetes management, highlighting its commitment to improving glycemic control and patient outcomes. Additionally, Lifecare is set to present promising data from its Sencell CGM development program at the ATTD conference in Amsterdam, showcasing the sensor’s competitive accuracy and potential for extended use.
More about Lifecare AS
Lifecare ASA is a clinical stage medical sensor company focused on developing next-generation Continuous Glucose Monitoring (CGM) systems. The company utilizes osmotic pressure as a sensing principle and manipulates Nano-granular Tunnelling Resistive sensors for monitoring various body analytes, aiming to revolutionize glucose monitoring with increased accuracy and longevity.
YTD Price Performance: -9.49%
Average Trading Volume: 445
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €15.13M
Learn more about LFC0 stock on TipRanks’ Stock Analysis page.